Keymed Biosciences Inc (HKSE:02162) Share Price

Company Profile

Business description
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
Contact
No. 18 BioTown Middle Road
Building D2
Tianfu International BioTown, Chengdu
Sichuan610219
CHN
T: +86 2888610620
https://www.keymedbio.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,116

Recommended

These two ASX shares are trading at a discount to our fair value.

Morningstar | 24 February 2025

Board members step down over differences on the role of former CEO Richard White.

Roy van Keulen | 24 February 2025

Morningstar's Chief Investment Officer for Asia-Pacific and Director of Personal Finance share their thoughts on the recent RBA rate cut.

Matt Wacher | 21 February 2025

Index	Last price	Change	% Change
All Ordinaries	8,494.50	65.60	-0.77%
CAC 40	8,090.99	63.52	-0.78%
DAX 40	22,425.93	138.37	0.62%
Dow JONES (US)	43,461.21	33.19	0.08%
FTSE 100	8,658.98	0.39	-0.00%
HKSE	22,998.69	342.92	-1.47%
NASDAQ	19,286.93	237.08	-1.21%
Nikkei 225	38,345.99	430.95	-1.11%
NZX 50 Index	12,355.74	175.98	-1.40%
S&P 500	5,983.25	29.88	-0.50%
S&P/ASX 200	8,247.00	61.20	-0.74%
SSE Composite Index	3,359.27	13.76	-0.41%